Updating the OMERACT filter: Implications for imaging and soluble biomarkers

Maria-Antonietta D'Agostino, Maria Antonietta D'Agostino, Maarten Boers, John Kirwan, Désirée Van Der Heijde, Mikkel Østergaard, Georg Schett, Robert B. Landewé, Walter P. Maksymowych, Esperanza Naredo, Maxime Dougados, Annamaria Iagnocco, Clifton O. Bingham, Peter M. Brooks, Dorcas E. Beaton, Frederique Gandjbakhch, Laure Gossec, Francis Guillemin, Sarah E. Hewlett, Margreet KloppenburgLyn March, Philip J. Mease, Ingrid Moller, Lee S. Simon, Jasvinder A. Singh, Vibeke Strand, Richard J. Wakefield, George A. Wells, Peter Tugwell, Philip G. Conaghan

Risultato della ricerca: Contributo in rivistaArticolo in rivista

11 Citazioni (Scopus)


Objective. The Outcome Measures in Rheumatology (OMERACT) Filter provides a framework for the validation of outcome measures for use in rheumatology clinical research. However, imaging and biochemical measures may face additional validation challenges because of their technical nature. The Imaging and Soluble Biomarker Session at OMERACT 11 aimed to provide a guide for the iterative development of an imaging or biochemical measurement instrument so it can be used in therapeutic assessment. Methods. A hierarchical structure was proposed, reflecting 3 dimensions needed for validating an imaging or biochemical measurement instrument: outcome domain(s), study setting, and performance of the instrument. Movement along the axes in any dimension reflects increasing validation. For a given test instrument, the 3-axis structure assesses the extent to which the instrument is a validated measure for the chosen domain, whether it assesses a patient-centered or disease-centered variable, and whether its technical performance is adequate in the context of its application. Some currently used imaging and soluble biomarkers for rheumatoid arthritis, spondyloarthritis, and knee osteoarthritis were then evaluated using the original OMERACT Filter and the newly proposed structure. Breakout groups critically reviewed the extent to which the candidate biomarkers complied with the proposed stepwise approach, as a way of examining the utility of the proposed 3-dimensional structure. Results. Although there was a broad acceptance of the value of the proposed structure in general, some areas for improvement were suggested including clarification of criteria for achieving a certain level of validation and how to deal with extension of the structure to areas beyond clinical trials. Conclusion. General support was obtained for a proposed tri-axis structure to assess validation of imaging and soluble biomarkers; nevertheless, additional work is required to better evaluate its place within the OMERACT Filter 2.0. © 2014. All rights reserved.
Lingua originaleEnglish
pagine (da-a)1016-1024
Numero di pagine9
Stato di pubblicazionePubblicato - 2014


  • Biomarkers
  • Clinical Trials as Topic
  • Humans
  • Imaging
  • Omeract filter
  • Outcome and Process Assessment, Health Care
  • Outcome and process assessment
  • Reproducibility of Results
  • Rheumatic Diseases
  • Rheumatology
  • Validation framework


Entra nei temi di ricerca di 'Updating the OMERACT filter: Implications for imaging and soluble biomarkers'. Insieme formano una fingerprint unica.

Cita questo